Aditya Bardia MD

Oncology•Santa Monica, CA

Attending Physician, Massachusetts General Hospital, Harvard Medical School

Join to View Full Profile

2336 Santa Monica BlvdSte 304Santa Monica, CA 90404
Phone+1 310-998-4747

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
All India Institute of Medical SciencesClass of 2003

Certifications & Licensure

CA State Medical License 2024 - 2026
MA State Medical License 2011 - 2025
MD State Medical License 2008 - 2012
MN State Medical License 2007 - 2008
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
Completed
Phase 3
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Start of enrollment: 2012 Dec 17
Completed
Phase 1, Phase 2
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Start of enrollment: 2014 Dec 29
Terminated
Phase 1, Phase 2
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
Completed
Phase 1
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) Start of enrollment: 2017 Nov 07
Completed
Phase 3
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Start of enrollment: 2016 Mar 09
Completed
Phase 1, Phase 2
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer Start of enrollment: 2017 Dec 12
ACTIVE_NOT_RECRUITING
PHASE2
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer Start of enrollment: 2017 Nov 08
TERMINATED
PHASE1
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) Start of enrollment: 2019 May 30
Active, not recruiting
Phase 1
A Study of TAS-120 in Patients With Metastatic Breast Cancer Start of enrollment: 2020 Jan 28
COMPLETED
PHASE2
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. Start of enrollment: 2019 Oct 09
RECRUITING
PHASE1, PHASE2
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Start of enrollment: 2019 Dec 10
ACTIVE_NOT_RECRUITING
PHASE1
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery Start of enrollment: 2021 Apr 21
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Circulating tumor DNA detection of local recurrence in a patient with early stage triple-negative breast cancer.
Samer Alkassis, Yashila Suresh, Marla Lipsyc-Sharf, Shiliang Zhang, Caterina Gianni
Breast Cancer Research and Treatment. 2025-09-01
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan.
Hope Rugo, Aditya Bardia, Debora S Bruno, Vinicius Ernani, Erika Hamilton
Supportive Care in Cancer. 2025-08-05
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
Arielle J Medford, Marko Velimirovic, Yifat Gefen, Andrzej Niemierko, Lorenzo Gerratana
Breast Cancer Research and Treatment. 2025-08-01

Journal Articles

Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
Aditya Bardia, MD, Clinical Cancer Research
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
David T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research

Lectures

Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic br...
2019 ASCO Annual Meeting - 6/1/2019
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2âˆ’ advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safe...
2019 ASCO Annual Meeting - 6/1/2019
Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC).
2019 ASCO Annual Meeting - 6/1/2019
EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigatorâ€™s choice (IC) of endocrine therap...
2019 ASCO Annual Meeting - 6/1/2019
Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreati...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast CancerJuly 8th, 2025
Challenging Cases in Metastatic Breast CancerMay 15th, 2025
Cancer Drug Dosing Concerns Highlighted by Patient-Led StudyAugust 13th, 2024
Join now to see all

Grant Support

Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancerMASSACHUSETTS GENERAL HOSPITAL2022–2026
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancerMASSACHUSETTS GENERAL HOSPITAL2022–2026